Buscar resultados de ensayos clínicos
Scleroderma, Diffuse - 20 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis Condición: Systemic Sclerosis Fecha: 2008-04-23 |
Recruiting |
Nombre del estudio: Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Condición: Scleroderma Fecha: 2015-01-26 Intervenciones:
|
Completed |
Nombre del estudio: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Condición: Systemic Sclerosis Fecha: 2012-08-15 Intervenciones: Drug: Belimumab Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the t |
Completed |
Nombre del estudio: A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Condición:
|
Completed |
Nombre del estudio: Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement Condición: Scleroderma, Systemic Fecha: 2006-06-02 Intervenciones: Drug: Mycophenolate mofetil |
Active, not recruiting |
Nombre del estudio: IVIG Treatment in Systemic Sclerosis Condición:
|
Recruiting |
Nombre del estudio: Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial Condición: Scleroderma Fecha: 2011-09-29 Intervenciones:
|
Completed |
Nombre del estudio: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial Condición: Systemic Scleroderma Fecha: 2015-01-18 Intervenciones:
|
Recruiting |
Nombre del estudio: Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis Condición:
|
Completed |
Nombre del estudio: High Dose Cyclophosphamide for Treatment of Scleroderma Condición: Scleroderma Fecha: 2007-07-13 Intervenciones: Drug: IV Cyclophosphamide Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total |